Search
Cupric sulfate
go.drugbank.com/drugs/DB06778ApprovedCupric sulfate is a salt created by treating cupric oxide with sulfuric acid. … The anhydrous salt is created by heating the hydrate to 150 °C (300 °F). Cupric sulfate is used primarily for agricultural purposes, as a pesticide, germicide, feed additive, and soil additive.
Mixtures: Pnv-VP-UCategories: Compounds used in a research, industrial, or household settingRitonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalRitonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].[L40094] … First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseOxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawn[A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations. … Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseDeutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Baloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018. … [L4779] It was also approved by the European Commission on January 7, 2021.[L45241]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseOcriplasmin
go.drugbank.com/drugs/DB08888ApprovedWithdrawnOcriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
Evening primrose oil
go.drugbank.com/drugs/DB11358ApprovedNutraceuticalEvening primrose oil comes from the extraction from _Oenothera biennis_ seeds and it is commonly used as an alternative source for omega-6 essential fatty acids. … [A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety".
Zilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigational[L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication. … [A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis.
Ferric cation
go.drugbank.com/drugs/DB13949ApprovedWithdrawnNon-haem iron in food is mainly in the ferric state, which is the insoluble form of iron, and must be reduced to the ferrous cation for absorption [T28]. … By mass, it is the most common element on Earth.
Mixtures: FERPLEX FOL, FERPLEX FOLFinerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors. … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart